UNSPSC 51412601: Nitroprusside

This classification denotes a vasodilating agent and diagnostic reagent with the molecular formula C5FEN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 169D1260KM. European Medicines Agency schedules nitroprusside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14660MIG. As of Q4 2014, NITROPRUSSIDE remains the US FDA Preferred Term for this commodity. Nitroprusside bears US NLM identifiers UMLS ID C0028193 and NCI Concept Code C77153.

SMILES: [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Na+].[Na+].[Fe].

UNSPSC 51412601 Nitroprusside is a Commodity code covering specific emergency and critical-care pharmaceutical products procured by state and local health and safety agencies. State and local governments buy nitroprusside and related advanced life support medications—intravenous vasodilators, vasopressors, cardiac agents, and antiarrhythmics—primarily for fire rescue, emergency medical services, and state health benefit programs. Recent solicitations show procurement focused on bulk supply agreements for emergency departments and paramedic services, with vendors supplying multiple medication line items under firm-price contracts that include expiration-date guarantees, rapid fulfillment (ten calendar days or less), and strict compliance with FDA manufacturing standards, OSHA Safety Data Sheets, and Section 508 accessibility documentation. Issuing bodies include city fire rescue departments (Tampa Fire Rescue in Hillsborough County), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances serving aggregated state and local facilities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, with participation from Oregon and other jurisdictions). The City of Tampa issued an IFB for Advanced Life Support Medications (Solicitation 26P00188) on April 24, 2026, with a due date of April 8, 2026, seeking 370 units of Labetalol, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine, and 1,020 units of Diltiazem for one-year supply with a $40,000 estimated contract value and a 5 percent bid discount for Small Local Business Enterprise participation.

Activity under the code concentrates in the South and Midwest, with recent procurement spanning Florida (Tampa), Texas (state HHS), and Minnesota (MMCAP cooperative covering multiple states including Oregon). The Texas HHS Commission issued a Request for Information (RFI No. HHS0017013, posted April 3, 2026, response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal RFP activity focused on direct contracts with manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802, posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with contract terms of two years for new vendors and aligned extensions through June 30, 2028 for incumbents. Award will be made to the lowest responsive, responsible bidder; vendors must maintain manufacturing compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and all products must carry expiration dates of at least one year from manufacture with a minimum six-month shelf life.